ClinicalTrials.Veeva

Menu

Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients

K

Kasr El Aini Hospital

Status and phase

Unknown
Phase 1

Conditions

Infertility

Treatments

Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine

Study type

Interventional

Funder types

Other

Identifiers

NCT02493933
43-2015

Details and patient eligibility

About

To evaluate the effect of oral Phytoestrogen or Isosorbid mononitrate or N-acetyl cysteine as an adjuvant to clomiphene citrate on induction of ovulation and pregnancy outcomes in patients with PCOS. In this three-arm open RCT, 240 PCOS infertile women were randomly divided to 3 groups for induction of ovulation. Group A, [PE group, n= 80] patients received CC 100mg/d plus oral Phytoestrogen120 mg/ day and patients in Group B, [ISMN group, n=80] received CC 100 mg/d plus 20 mg Isosorbid mononitrate and Group C, [NAC group, n=80] patients received CC 100 mg/d plus NAC 1200 mg/day.

Enrollment

240 estimated patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. All patients have PCOS.
  2. All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved.
  3. All patients have patent fallopian tubes by Hysterosalpingography.
  4. Their husbands have normal semen analysis according to the modified criteria of WHO.
  5. All patients have normal serum prolactin and thyroid profile.
  6. Any patient having vaginitis was treated before starting induction.

Exclusion criteria

  1. Other causes of infertility than anovulation.
  2. Diabetes or other endocrinological disorders.
  3. Age > 40 years.
  4. Smoking.
  5. Alcohol use.
  6. Presence of ovarian cyst >2cm on the second day of the cycle.
  7. Patients who have received gonadotrophins in the preceeding 6 months.
  8. Patients who have done unilateral or bilateral ovarian drilling.
  9. Allergy to PE, NO donors or NAC

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 3 patient groups

Phytoestrogen
Active Comparator group
Description:
Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
Treatment:
Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Isosorbid mononitrate
Active Comparator group
Description:
Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
Treatment:
Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
N-Acetyl cysteine
Active Comparator group
Description:
Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
Treatment:
Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems